<DOC>
	<DOCNO>NCT02432365</DOCNO>
	<brief_summary>The purpose establish quick ( 7-day ) cycle schedule paclitaxel ( 60 mg/m2 ) combine cisplatin ( 40 mg/m2 ) NAC regimen could tolerate without interfere follow surgical treatment favorable overall survival rate stage IB2 IIA2 cervical squamous cell carcinoma ( SCC ) .</brief_summary>
	<brief_title>Study Weekly Paclitaxel Cisplatin FIGO IB2 IIA2 Cervical Cancer Followed Radical Hysterectomy</brief_title>
	<detailed_description>This multi-center , open-label , Simon 's 2-stage , phase II study paclitaxel cisplatin neoadjuvant therapy patient FIGO IB2 IIA2 , squamous cell cervical carcinoma uterine cervix . Primary Objectives : â€¢ Overall survival Secondary Objectives : - Safety - Progression-free survival - Response rate - Postoperative RT/CRT rate - To assess Quality-of-life An estimate 64 evaluable patient enrol phase II investigation .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Women previously ultreated , histologically confirm squamous cell carcinoma uterine cervix 2 . HPV16positive aged 3570 year HPV16negative age &lt; 55 year , ( age 5570 , eligibility confirm HPV genotype result know . Therefore , inform consent sign earlier 2 week HPV genotyping ) 3 . FIGO stage IB2 bulky IIA , tumor extend vagina within upper one third vaginal wall . Bulky tumor define ( ) visible cervical tumor large diameter &gt; 4 cm ( b ) cervix expand &gt; 4 cm result tumor infiltration pelvic examination ( b ) verify magnetic resonance image ( MRI ) 3dimensional ( D ) compute tomography ( CT ) 4. suspicious extrapelvic metastasis detect MRI 3D CT 5. adequate marrow , liver renal function 6. adequate cardiopulmonary function tolerate administration study regimen radical hysterectomy 7 . Eastern Cooperative Oncology Group performance status 0 1 8. write informed consent participate study 9 . Appropriate organ marrow function 10. negative urinary pregnancy test patient childbearing potential 1 . Patients exclude study meet follow criterion : concurrent history malignant tumor ( ) treat nonmelanoma skin cancer 2. receive surgical procedure cervical biopsy cytotoxic procedure include chemotherapy , radiotherapy therapy biologic response modifier ( ) cervical tumor 3. enlarge pelvic lymph node positive aspiration cytologic histologic study 4. participate investigational treatment another clinical trial cervical cancer 5. history allergic reaction platinum paclitaxel 6. uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 7. pregnant breast feeding woman</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Paclitaxel</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>Radical hysterectomy</keyword>
	<keyword>Neoadjuvant</keyword>
</DOC>